2001年1月
Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis
LANCET
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 357
- 号
- 9251
- 開始ページ
- 196
- 終了ページ
- 197
- 記述言語
- 英語
- 掲載種別
- DOI
- 10.1016/S0140-6736(00)03595-9
- 出版者・発行元
- LANCET LTD
In a prospective randomised controlled study, 90 patients with chronic active hepatitis C and compensated cirrhosis were assigned symptomatic treatment or interferon alfa (IFN-alpha). We report data on decompensation, detection of hepatocellular carcinoma, and mortality rates, IFN-alpha gave a sustained response in only a small proportion of patients, but worsening of compensated cirrhosis was prevented and development of hepatocellular carcinoma was Inhibited, increasing the survival rate. The risk ratio of IFN-alpha versus symptomatic treatment decreased by 0.250 for progression to Child-Pugh grade B, 0.256 for detection of hepatocellular carcinoma, and 0.135 for a fatal outcome.
- リンク情報
- ID情報
-
- DOI : 10.1016/S0140-6736(00)03595-9
- ISSN : 0140-6736
- Web of Science ID : WOS:000166593700015